## Edgar Filing: ACCELERON PHARMA INC - Form 4

ACCELERC Form 4 October 21, 2	ON PHARMA INC	2	g								
	_								OMB A	PPROVAL	
FORN	SECURITIES AND EXCHANGE ( Washington, D.C. 20549					COMMISSION	OMB Number:	3235-0287			
Check the if no long	F CHANGES IN BENEFICIAL OW SECURITIES						Expires:	January 31, 2005			
subject to Section 1 Form 4 o						NERSHIP OF	Estimated a burden hou response	ours per			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> Kumar Ravindra			2. Issuer Name <b>and</b> Ticker or Trading Symbol				-	5. Relationship of Reporting Person(s) to Issuer			
		ACCELERON PHARMA INC [XLRN]					(Check all applicable)				
(Last)					Date of Earliest Transaction				Director 10% Owner X Officer (give title Other (specify		
128 SIDNEY STREET			(Month/Day/Year) 10/19/2015					below) below) VP & Chief Scientific Officer			
			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line)			
CAMBRID						_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State) (A	Zip)	Table	e I - Non-D	erivative	Securi	ities Acc	uired, Disposed of	f, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	on Date, if Transaction(A) or Disposed of Code (D) Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)					
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	10/19/2015			М	2,300	А	\$ 1.8	58,985	D		
Common Stock	10/19/2015			М	6,250	А	\$ 5.08	65,235	D		
Common Stock	10/19/2015			М	5,516	А	\$ 5.28	70,751	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

### Edgar Filing: ACCELERON PHARMA INC - Form 4

#### number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number out Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	e Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Option to Purchase Common Stock	\$ 1.8	10/19/2015		М	2,300	) (1)	06/12/2017	Common Stock	2,300	
Option to Purchase Common Stock	\$ 5.08	10/19/2015		М	6,250	) (1)	03/27/2018	Common Stock	6,250	
Option to Purchase Common Stock	\$ 5.28	10/19/2015		М	5,510	5 <u>(1)</u>	12/16/2021	Common Stock	5,516	

## **Reporting Owners**

Reporting Owner Name / Address	ress Relationships						
	Director	10% Owner	Officer	Other			
Kumar Ravindra 128 SIDNEY STREET CAMBRIDGE, MA 02139			VP & Chief Scientific Officer				
Signatures							
/s/ John D. Quisel, as attorney-i Kumar	n-fact for	r Ravindra	10/21/2015				

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). \*
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). \*\*
- (1) The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant.

## Edgar Filing: ACCELERON PHARMA INC - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.